A key limitation across aminofunctionalizations is incompatibility with substrates bearing medicinally relevant N-heterocycles; in contrast, this aerobic, Cu-catalyzed aminooxygenation engages a diverse range of N-heterocycle-bearing substrates.
We report a method for a ligand-enabled, copper-catalyzed, aerobic aminooxygenation of internal alkenes. The synergistic combination of a phenanthroline-based ligand and substrate coordination promotes reduction of Cu(II) to Cu(I), resulting in a cyclization that proceeds via an amidyl radical pathway rather than a previously-established aminocupration path-way. The complementary reactivity enabled by this switch in reaction mechanism provides access to new substrate classes and a considerably broadened scope for this transformation. Experimental evidence supports a free radical mechanism involving substrate-promoted reduction to Cu(I) as well as the role of O2 as both oxidant and functionalizing agent.
Despite the maturity of alkene 1,2-difunctionalization reactions involving C–N bond formation, a key limitation across aminofunctionalization methods is incompatibility with substrates bearing medicinally relevant N-heterocycles. Using a cooperative ligand-substrate catalyst activation strategy, we have developed an aerobic, copper-catalyzed alkene aminooxygenation method that exhibits broad tolerance for β,γ-unsaturated carbamates bearing aromatic azaheterocycle substitution. The synthetic potential of this methodology was demonstrated by engaging a densely-functionalized vonoprazan analogue and elaborating an aminooxygenated product to synthesize a heteroarylated analogue precursor of the FDA-approved antibiotic chloramphenicol.